The final analyzed cohort included 30 donors with diverse risk of AD, including reduced risk in E2+ APOE carriers (n=14) and increased risk in E4+ APOE carriers (n=16, Figure 1A, Table S1)7,22,23. The gene discussed is APOE; the disease is Alzheimer disease.